Estrella Immunopharma, Inc. - 10-Q Filing
Estrella Immunopharma filed its quarterly report for the period ended March 31, 2026, reporting a net loss of $2.29 million and a basic and diluted net loss per share of $0.05. The company had cash and equivalents totaling $1.93 million as of March 31, 2026.
Tickers: $ESLA